Skin Cutaneous Melanoma: Mutation Analysis (MutSig v1.5)
(All_Primary cohort)
Maintained by Dan DiCara (Broad Institute)
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v1.5 was used to generate the results found in this report.

- Working with individual set: SKCM-All_Primary

- Number of patients in set: 38

Input

The input for this pipeline is a set of individuals with the following files associated for each:

1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

2. A .wig file that contains information about the coverage of the sample.

Summary

- MAF used for this analysis:SKCM-All_Primary.final_analysis_set.maf

- Significantly mutated genes (q ≤ 0.1): 19

- Mutations seen in COSMIC: 81

- Significantly mutated genes in COSMIC territory: 5

- Genes with clustered mutations (≤ 3 aa apart): 148

- Significantly mutated genesets: 4

- Significantly mutated genesets: (excluding sig. mutated genes):0

Mutation Preprocessing

- Read 38 MAFs of type "Broad"

- Total number of mutations in input MAFs: 18327

- After removing 1 mutations outside chr1-24: 18326

- After removing 135 blacklisted mutations: 18191

- After removing 368 noncoding mutations: 17823

Mutation Filtering

- Number of mutations before filtering: 17823

- After removing 240 mutations outside gene set: 17583

- After removing 3 mutations outside category set: 17580

Results
Breakdown of Mutations by Type

Table 1. Get Full Table Table representing breakdown of mutations by type.

type | count
--- | ---
Frame_Shift_Del | 101
Frame_Shift_Ins | 36
In_Frame_Del | 32
In_Frame_Ins | 8
Missense_Mutation | 10885
Nonsense_Mutation | 682
Nonstop_Mutation | 3
Silent | 5642
Splice_Site | 180
Translation_Start_Site | 11
Total | 17580

Breakdown of Mutation Rates by Category Type

Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.

category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio
--- | --- | --- | --- | --- | --- | ---
(C/T)p*C->T | 8028 | 304598383 | 0.000026 | 26 | 2.4 | 1.6
(A/G)p*C->T | 970 | 255685633 | 3.8e-06 | 3.8 | 0.35 | 1.9
A->G | 505 | 540676925 | 9.3e-07 | 0.93 | 0.086 | 2.3
transver | 1391 | 1100960941 | 1.3e-06 | 1.3 | 0.12 | 5
indel+null | 1041 | 1100960941 | 9.5e-07 | 0.95 | 0.087 | NaN
double_null | 3 | 1100960941 | 2.7e-09 | 0.0027 | 0.00025 | NaN
Total | 11938 | 1100960941 | 0.000011 | 11 | 1 | 3.5

Target Coverage for Each Individual

The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).

Figure 1.

Distribution of Mutation Counts, Coverage, and Mutation Rates Across Samples

Figure 2. Patients counts and rates file used to generate this plot: SKCM-All_Primary.patients.counts_and_rates.txt

CoMut Plot

Figure 3. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

- N = number of sequenced bases in this gene across the individual set

- n = number of (nonsilent) mutations in this gene across the individual set

- npat = number of patients (individuals) with at least one nonsilent mutation

- nsite = number of unique sites having a non-silent mutation

- nsil = number of silent mutations in this gene across the individual set

- n1 = number of nonsilent mutations of type: (C/T)p*C->T

- n2 = number of nonsilent mutations of type: (A/G)p*C->T

- n3 = number of nonsilent mutations of type: A->G

- n4 = number of nonsilent mutations of type: transver

- n5 = number of nonsilent mutations of type: indel+null

- n6 = number of nonsilent mutations of type: double_null

- p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene

- p = p-value (overall)

- q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 19. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 84542 | 24 | 23 | 4 | 0 | 1 | 0 | 1 | 22 | 0 | 0 | 0.0077 | 1.1e-15 | 2e-11
2 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 22263 | 6 | 6 | 1 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0.12 | 9.9e-12 | 8.9e-08
3 | FAM135B | family with sequence similarity 135, member B | 163134 | 13 | 13 | 12 | 1 | 9 | 0 | 0 | 3 | 1 | 0 | 0.029 | 1e-08 | 0.000062
4 | PRB2 | proline-rich protein BstNI subfamily 2 | 47532 | 9 | 8 | 7 | 0 | 7 | 0 | 0 | 2 | 0 | 0 | 0.25 | 3.9e-08 | 0.00018
5 | TLL1 | tolloid-like 1 | 115472 | 10 | 9 | 10 | 1 | 6 | 1 | 0 | 0 | 3 | 0 | 0.19 | 4.6e-07 | 0.0017
6 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 43686 | 5 | 5 | 5 | 0 | 1 | 0 | 1 | 0 | 3 | 0 | 0.32 | 8.5e-07 | 0.0026
7 | PPP6C | protein phosphatase 6, catalytic subunit | 38199 | 5 | 5 | 4 | 0 | 4 | 0 | 0 | 0 | 1 | 0 | 0.18 | 0.000017 | 0.04
8 | ARID2 | AT rich interactive domain 2 (ARID, RFX-like) | 208651 | 9 | 8 | 9 | 1 | 2 | 0 | 0 | 0 | 7 | 0 | 0.32 | 0.000018 | 0.04
9 | ADCYAP1R1 | adenylate cyclase activating polypeptide 1 (pituitary) receptor type I | 54688 | 5 | 5 | 5 | 1 | 2 | 1 | 1 | 0 | 1 | 0 | 0.24 | 0.000026 | 0.046
10 | GLYAT | glycine-N-acyltransferase | 33932 | 4 | 4 | 4 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0.23 | 0.000029 | 0.046
11 | CLVS1 | clavesin 1 | 41091 | 6 | 6 | 5 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0.052 | 0.000029 | 0.046
12 | CFHR1 | complement factor H-related 1 | 32025 | 6 | 5 | 6 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0.26 | 0.000031 | 0.046
13 | ZFHX4 | zinc finger homeobox 4 | 354049 | 12 | 11 | 12 | 1 | 6 | 2 | 1 | 3 | 0 | 0 | 0.065 | 0.000044 | 0.062
14 | KCNC2 | potassium voltage-gated channel, Shaw-related subfamily, member 2 | 62606 | 5 | 5 | 5 | 0 | 2 | 1 | 0 | 1 | 1 | 0 | 0.11 | 0.000051 | 0.063
15 | FAM5C | family with sequence similarity 5, member C | 87218 | 8 | 7 | 8 | 2 | 5 | 0 | 0 | 3 | 0 | 0 | 0.39 | 0.000052 | 0.063
16 | GRM8 | glutamate receptor, metabotropic 8 | 105539 | 7 | 6 | 7 | 0 | 3 | 1 | 2 | 0 | 1 | 0 | 0.047 | 0.000058 | 0.064
17 | OR5T3 | olfactory receptor, family 5, subfamily T, member 3 | 38603 | 4 | 4 | 4 | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 0.39 | 0.000062 | 0.064
18 | PPP1R3A | protein phosphatase 1, regulatory (inhibitor) subunit 3A | 125297 | 7 | 7 | 7 | 1 | 5 | 0 | 1 | 1 | 0 | 0 | 0.4 | 0.000064 | 0.064
19 | SCAND3 | SCAN domain containing 3 | 146281 | 10 | 7 | 10 | 0 | 6 | 1 | 2 | 1 | 0 | 0 | 0.031 | 0.000067 | 0.064
20 | KRTAP4-7 | keratin associated protein 4-7 | 13851 | 2 | 2 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0.88 | 0.00012 | 0.1
21 | OR10A7 | olfactory receptor, family 10, subfamily A, member 7 | 34863 | 3 | 3 | 3 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0.53 | 0.00012 | 0.1
22 | OR8I2 | olfactory receptor, family 8, subfamily I, member 2 | 34565 | 4 | 4 | 4 | 1 | 3 | 0 | 1 | 0 | 0 | 0 | 0.25 | 0.00013 | 0.11
23 | CAPN13 | calpain 13 | 62498 | 6 | 6 | 6 | 1 | 5 | 0 | 1 | 0 | 0 | 0 | 0.18 | 0.00014 | 0.11
24 | TP53 | tumor protein p53 | 46527 | 4 | 4 | 4 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 0.17 | 0.00015 | 0.11
25 | OR52E4 | olfactory receptor, family 52, subfamily E, member 4 | 35508 | 4 | 4 | 4 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0.19 | 0.00016 | 0.11
26 | TNFSF14 | tumor necrosis factor (ligand) superfamily, member 14 | 26552 | 4 | 4 | 4 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0.097 | 0.00017 | 0.12
27 | GRIA1 | glutamate receptor, ionotropic, AMPA 1 | 108856 | 7 | 7 | 7 | 2 | 3 | 0 | 0 | 2 | 2 | 0 | 0.28 | 0.00018 | 0.12
28 | C7 | complement component 7 | 83984 | 9 | 7 | 9 | 0 | 8 | 0 | 0 | 0 | 1 | 0 | 0.054 | 0.00019 | 0.12
29 | KCNE1 | potassium voltage-gated channel, Isk-related family, member 1 | 14972 | 3 | 3 | 3 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0.12 | 0.0002 | 0.13
30 | LELP1 | late cornified envelope-like proline-rich 1 | 11263 | 3 | 3 | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0.47 | 0.00022 | 0.14
31 | IL7R | interleukin 7 receptor | 53335 | 6 | 5 | 6 | 1 | 3 | 0 | 0 | 2 | 1 | 0 | 0.29 | 0.00024 | 0.14
32 | GIMAP5 | GTPase, IMAP family member 5 | 35413 | 5 | 4 | 5 | 1 | 3 | 1 | 0 | 1 | 0 | 0 | 0.21 | 0.00024 | 0.14
33 | NPHP1 | nephronophthisis 1 (juvenile) | 85394 | 4 | 4 | 3 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0.28 | 0.00026 | 0.14
34 | OR8D1 | olfactory receptor, family 8, subfamily D, member 1 | 31504 | 4 | 4 | 4 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 0.085 | 0.00028 | 0.15
35 | OR52M1 | olfactory receptor, family 52, subfamily M, member 1 | 36275 | 4 | 4 | 4 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 0.1 | 0.00032 | 0.15

BRAF

Figure S1. This figure depicts the distribution of mutations and mutation types across the BRAF significant gene.

NRAS

Figure S2. This figure depicts the distribution of mutations and mutation types across the NRAS significant gene.

FAM135B

Figure S3. This figure depicts the distribution of mutations and mutation types across the FAM135B significant gene.

TLL1

Figure S4. This figure depicts the distribution of mutations and mutation types across the TLL1 significant gene.

PTEN

Figure S5. This figure depicts the distribution of mutations and mutation types across the PTEN significant gene.

PPP6C

Figure S6. This figure depicts the distribution of mutations and mutation types across the PPP6C significant gene.

ARID2

Figure S7. This figure depicts the distribution of mutations and mutation types across the ARID2 significant gene.

ADCYAP1R1

Figure S8. This figure depicts the distribution of mutations and mutation types across the ADCYAP1R1 significant gene.

GLYAT

Figure S9. This figure depicts the distribution of mutations and mutation types across the GLYAT significant gene.

CLVS1

Figure S10. This figure depicts the distribution of mutations and mutation types across the CLVS1 significant gene.

CFHR1

Figure S11. This figure depicts the distribution of mutations and mutation types across the CFHR1 significant gene.

ZFHX4

Figure S12. This figure depicts the distribution of mutations and mutation types across the ZFHX4 significant gene.

KCNC2

Figure S13. This figure depicts the distribution of mutations and mutation types across the KCNC2 significant gene.

FAM5C

Figure S14. This figure depicts the distribution of mutations and mutation types across the FAM5C significant gene.

GRM8

Figure S15. This figure depicts the distribution of mutations and mutation types across the GRM8 significant gene.

OR5T3

Figure S16. This figure depicts the distribution of mutations and mutation types across the OR5T3 significant gene.

PPP1R3A

Figure S17. This figure depicts the distribution of mutations and mutation types across the PPP1R3A significant gene.

SCAND3

Figure S18. This figure depicts the distribution of mutations and mutation types across the SCAND3 significant gene.

COSMIC analyses

In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.

Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 5. Number of genes displayed: 10

rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 24 | 89 | 23 | 3382 | 330218 | 0 | 0
2 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 6 | 33 | 6 | 1254 | 7788 | 0 | 0
3 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 3 | 5 | 2 | 190 | 2984 | 2.1e-06 | 0.0032
4 | TP53 | tumor protein p53 | 4 | 356 | 4 | 13528 | 1243 | 0.000017 | 0.018
5 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 5 | 767 | 5 | 29146 | 211 | 2e-05 | 0.018
6 | CBL | Cas-Br-M (murine) ecotropic retroviral transforming sequence | 3 | 45 | 2 | 1710 | 7 | 0.00017 | 0.13
7 | ADAM2 | ADAM metallopeptidase domain 2 (fertilin beta) | 3 | 1 | 1 | 38 | 1 | 0.00041 | 0.16
8 | F13A1 | coagulation factor XIII, A1 polypeptide | 2 | 1 | 1 | 38 | 1 | 0.00041 | 0.16
9 | GLRA2 | glycine receptor, alpha 2 | 1 | 1 | 1 | 38 | 1 | 0.00041 | 0.16
10 | NAP1L2 | nucleosome assembly protein 1-like 2 | 3 | 1 | 1 | 38 | 1 | 0.00041 | 0.16

Note:

n - number of (nonsilent) mutations in this gene across the individual set.

cos = number of unique mutated sites in this gene in COSMIC

n_cos = overlap between n and cos.

N_cos = number of individuals times cos.

cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.

p = p-value for seeing the observed amount of overlap in this gene)

q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Clustered Mutations

Table 5. Get Full Table Genes with Clustered Mutations

num | gene | desc | n | mindist | nmuts0 | nmuts3 | nmuts12 | npairs0 | npairs3 | npairs12
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
580 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 24 | 0 | 91 | 105 | 105 | 91 | 105 | 105
3776 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 6 | 0 | 15 | 15 | 15 | 15 | 15 | 15
1192 | CLIP1 | CAP-GLY domain containing linker protein 1 | 5 | 0 | 3 | 3 | 3 | 3 | 3 | 3
3263 | MAP2K1 | mitogen-activated protein kinase kinase 1 | 3 | 0 | 3 | 3 | 3 | 3 | 3 | 3
4491 | PRB2 | proline-rich protein BstNI subfamily 2 | 9 | 0 | 2 | 2 | 3 | 2 | 2 | 3
717 | C1orf173 | chromosome 1 open reading frame 173 | 10 | 0 | 2 | 2 | 2 | 2 | 2 | 2
6265 | ZNF208 | zinc finger protein 208 | 8 | 0 | 2 | 2 | 2 | 2 | 2 | 2
3517 | MUC16 | mucin 16, cell surface associated | 78 | 0 | 1 | 4 | 5 | 1 | 4 | 5
2041 | FLG2 | filaggrin family member 2 | 15 | 0 | 1 | 2 | 3 | 1 | 2 | 3
3438 | MORC1 | MORC family CW-type zinc finger 1 | 5 | 0 | 1 | 2 | 2 | 1 | 2 | 2

Note:

n - number of mutations in this gene in the individual set.

mindist - distance (in aa) between closest pair of mutations in this gene

npairs3 - how many pairs of mutations are within 3 aa of each other.

npairs12 - how many pairs of mutations are within 12 aa of each other.

Geneset Analyses

Table 6. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 4. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | ST_G_ALPHA_S_PATHWAY | The G-alpha-s protein activates adenylyl cyclases, which catalyze cAMP formation. | ASAH1, BF, BFAR, BRAF, CAMP, CREB1, CREB3, CREB5, EPAC, GAS, GRF2, MAPK1, RAF1, SNX13, SRC, TERF2IP | 12 | BFAR(1), BRAF(24), CREB5(2), TERF2IP(1) | 628058 | 28 | 25 | 8 | 1 | 3 | 0 | 1 | 24 | 0 | 0 | 0.014 | 5.1e-15 | 3.2e-12
2 | ST_ERK1_ERK2_MAPK_PATHWAY | The Erk1 and Erk2 MAP kinase pathways are regulated by Raf, Mos, and Tpl-2. | ARAF1, ATF1, BAD, BRAF, COPEB, CREB1, CREB3, CREB5, DUSP4, DUSP6, DUSP9, EEF2K, EIF4E, GRB2, HTATIP, MAP2K1, MAP2K2, MAP3K8, MAPK1, MAPK3, MKNK1, MKNK2, MOS, NFKB1, RAP1A, RPS6KA1, RPS6KA2, RPS6KA3, SHC1, SOS1, SOS2, TRAF3 | 29 | ATF1(1), BRAF(24), CREB5(2), DUSP4(2), EEF2K(2), EIF4E(1), MAP2K1(3), MAP2K2(1), RPS6KA1(3), RPS6KA2(1), SHC1(2), SOS1(1), SOS2(2) | 1650651 | 45 | 28 | 23 | 2 | 15 | 3 | 3 | 24 | 0 | 0 | 0.00011 | 6.5e-12 | 2e-09
3 | ST_DIFFERENTIATION_PATHWAY_IN_PC12_CELLS | Rat-derived PC12 cells respond to nerve growth factor (NGF) and PACAP to differentiate into neuronal cells. | AKT1, ASAH1, ATF1, BRAF, CAMP, CREB1, CREB3, CREB5, CREBBP, CRKL, DAG1, EGR1, EGR2, EGR3, EGR4, ELK1, FRS2, GAS, GNAQ, GRF2, JUN, MAP1B, MAP2K4, MAP2K7, MAPK1, MAPK10, MAPK3, MAPK8, MAPK8IP1, MAPK8IP2, MAPK8IP3, MAPK9, NTRK1, OPN1LW, PACAP, PIK3C2G, PIK3CA, PIK3CD, PIK3R1, PTPN11, RPS6KA3, SH2B, SHC1, SRC, TERF2IP, TH, TUBA3 | 42 | ATF1(1), BRAF(24), CREB5(2), CREBBP(3), DAG1(1), FRS2(1), GNAQ(2), MAPK10(1), MAPK8(1), MAPK8IP1(1), MAPK8IP2(2), MAPK8IP3(1), MAPK9(2), NTRK1(4), OPN1LW(1), PIK3C2G(7), PIK3CA(1), PIK3R1(4), PTPN11(1), SHC1(2), TERF2IP(1) | 2864884 | 63 | 30 | 43 | 5 | 20 | 3 | 4 | 31 | 5 | 0 | 0.000034 | 5.1e-09 | 1e-06
4 | ST_ADRENERGIC | Adrenergic receptors respond to epinephrine and norepinephrine signaling. | AKT1, APC, AR, ASAH1, BF, BRAF, CAMP, CCL13, CCL15, CCL16, DAG1, EGFR, GAS, GNA11, GNA15, GNAI1, GNAQ, ITPKA, ITPKB, ITPR1, ITPR2, ITPR3, KCNJ3, KCNJ5, KCNJ9, MAPK1, MAPK10, MAPK14, PHKA2, PIK3CA, PIK3CD, PIK3R1, PITX2, PTX1, PTX3, RAF1, SRC | 34 | APC(3), BRAF(24), CCL13(1), DAG1(1), EGFR(1), GNAQ(2), ITPKA(1), ITPR1(7), ITPR2(1), ITPR3(3), KCNJ3(4), KCNJ5(3), MAPK10(1), PIK3CA(1), PIK3R1(4) | 2987528 | 57 | 29 | 37 | 9 | 17 | 2 | 4 | 31 | 3 | 0 | 0.0045 | 0.00037 | 0.057
5 | MAPKPATHWAY | The mitogen-activated protein (MAP) kinase pathway is a common signaling mechanism and has four main sub-pathways: Erk, JNK/SAPK, p53, and ERK5. | ARAF1, ATF2, BRAF, CEBPA, CHUK, CREB1, DAXX, ELK1, FOS, GRB2, HRAS, IKBKB, JUN, MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K5, MAP2K6, MAP2K7, MAP3K1, MAP3K10, MAP3K11, MAP3K12, MAP3K13, MAP3K14, MAP3K2, MAP3K3, MAP3K4, MAP3K5, MAP3K6, MAP3K7, MAP3K8, MAP3K9, MAP4K1, MAP4K2, MAP4K3, MAP4K4, MAP4K5, MAPK1, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, MAPK3, MAPK4, MAPK6, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, MAPKAPK5, MAX, MEF2A, MEF2B, MEF2C, MEF2D, MKNK1, MKNK2, MYC, NFKB1, NFKBIA, PAK1, PAK2, PDZGEF1, RAC1, RAF1, RELA, RIPK1, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA5, RPS6KB1, RPS6KB2, SHC1, SP1, STAT1, TGFB1, TGFB2, TGFB3, TGFBR1, TRADD, TRAF2 | 84 | BRAF(24), DAXX(1), HRAS(1), IKBKB(1), MAP2K1(3), MAP2K2(1), MAP2K3(2), MAP3K1(1), MAP3K12(1), MAP3K14(1), MAP3K5(2), MAP3K9(2), MAP4K4(1), MAPK10(1), MAPK12(1), MAPK13(1), MAPK4(3), MAPK8(1), MAPK9(2), MAPKAPK3(1), MEF2B(1), MEF2C(1), MEF2D(1), MYC(1), RELA(1), RPS6KA1(3), RPS6KA2(1), RPS6KA4(1), SHC1(2), TRAF2(1) | 5298061 | 64 | 32 | 42 | 7 | 28 | 4 | 4 | 25 | 3 | 0 | 0.000066 | 0.0016 | 0.18
6 | HSA04320_DORSO_VENTRAL_AXIS_FORMATION | Genes involved in dorso-ventral axis formation | BRAF, CPEB1, EGFR, ERBB2, ERBB4, ETS1, ETS2, ETV6, ETV7, FMN2, GRB2, KRAS, MAP2K1, MAPK1, MAPK3, NOTCH1, NOTCH2, NOTCH3, NOTCH4, PIWIL1, PIWIL2, PIWIL3, PIWIL4, RAF1, SOS1, SOS2, SPIRE1, SPIRE2 | 28 | BRAF(24), EGFR(1), ERBB4(3), ETS1(1), ETS2(1), ETV6(2), FMN2(3), MAP2K1(3), NOTCH2(4), NOTCH4(3), PIWIL1(1), PIWIL2(2), PIWIL4(2), SOS1(1), SOS2(2) | 2938184 | 53 | 27 | 31 | 9 | 16 | 1 | 2 | 29 | 5 | 0 | 0.026 | 0.0021 | 0.18
7 | ARFPATHWAY | Cyclin-dependent kinase inhibitor 2A is a tumor suppressor that induces G1 arrest and can activate the p53 pathway, leading to G2/M arrest. | ABL1, CDKN2A, E2F1, MDM2, MYC, PIK3CA, PIK3R1, POLR1A, POLR1B, POLR1C, POLR1D, RAC1, RB1, TBX2, TP53, TWIST1 | 16 | CDKN2A(1), E2F1(2), MDM2(1), MYC(1), PIK3CA(1), PIK3R1(4), POLR1B(1), TP53(4) | 1134716 | 15 | 13 | 15 | 1 | 3 | 1 | 3 | 3 | 5 | 0 | 0.023 | 0.0021 | 0.18
8 | ERK5PATHWAY | Signaling between a tissue and its innervating axon stimulates retrograde transport via Trk receptors, which activate Erk5, which induces transcription of anti-apoptotic factors. | AKT1, CREB1, GRB2, HRAS, MAPK1, MAPK3, MAPK7, MEF2A, MEF2B, MEF2C, MEF2D, NTRK1, PIK3CA, PIK3R1, PLCG1, RPS6KA1, SHC1 | 17 | HRAS(1), MEF2B(1), MEF2C(1), MEF2D(1), NTRK1(4), PIK3CA(1), PIK3R1(4), RPS6KA1(3), SHC1(2) | 1061373 | 18 | 13 | 18 | 2 | 5 | 3 | 3 | 2 | 5 | 0 | 0.015 | 0.0024 | 0.19
9 | NKCELLSPATHWAY | Natural killer (NK) lymphocytes are inhibited by MHC and activated by surface glycoproteins on tumor or virus-infected cells, which undergo perforin-mediated lysis. | B2M, HLA-A, IL18, ITGB1, KLRC1, KLRC2, KLRC3, KLRC4, KLRD1, LAT, MAP2K1, MAPK3, PAK1, PIK3CA, PIK3R1, PTK2B, PTPN6, RAC1, SYK, VAV1 | 20 | B2M(1), KLRC1(1), MAP2K1(3), PIK3CA(1), PIK3R1(4), PTK2B(1), SYK(2), VAV1(2) | 1042544 | 15 | 12 | 13 | 1 | 8 | 1 | 1 | 2 | 3 | 0 | 0.014 | 0.0039 | 0.27
10 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | CDKN2A(1), E2F1(2), MDM2(1), PRB1(5), TP53(4) | 471635 | 13 | 9 | 13 | 1 | 7 | 1 | 2 | 1 | 2 | 0 | 0.02 | 0.0058 | 0.36

Table 7. Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | ARFPATHWAY | Cyclin-dependent kinase inhibitor 2A is a tumor suppressor that induces G1 arrest and can activate the p53 pathway, leading to G2/M arrest. | ABL1, CDKN2A, E2F1, MDM2, MYC, PIK3CA, PIK3R1, POLR1A, POLR1B, POLR1C, POLR1D, RAC1, RB1, TBX2, TP53, TWIST1 | 16 | CDKN2A(1), E2F1(2), MDM2(1), MYC(1), PIK3CA(1), PIK3R1(4), POLR1B(1), TP53(4) | 1134716 | 15 | 13 | 15 | 1 | 3 | 1 | 3 | 3 | 5 | 0 | 0.023 | 0.0021 | 0.75
2 | ERK5PATHWAY | Signaling between a tissue and its innervating axon stimulates retrograde transport via Trk receptors, which activate Erk5, which induces transcription of anti-apoptotic factors. | AKT1, CREB1, GRB2, HRAS, MAPK1, MAPK3, MAPK7, MEF2A, MEF2B, MEF2C, MEF2D, NTRK1, PIK3CA, PIK3R1, PLCG1, RPS6KA1, SHC1 | 17 | HRAS(1), MEF2B(1), MEF2C(1), MEF2D(1), NTRK1(4), PIK3CA(1), PIK3R1(4), RPS6KA1(3), SHC1(2) | 1061373 | 18 | 13 | 18 | 2 | 5 | 3 | 3 | 2 | 5 | 0 | 0.015 | 0.0024 | 0.75
3 | NKCELLSPATHWAY | Natural killer (NK) lymphocytes are inhibited by MHC and activated by surface glycoproteins on tumor or virus-infected cells, which undergo perforin-mediated lysis. | B2M, HLA-A, IL18, ITGB1, KLRC1, KLRC2, KLRC3, KLRC4, KLRD1, LAT, MAP2K1, MAPK3, PAK1, PIK3CA, PIK3R1, PTK2B, PTPN6, RAC1, SYK, VAV1 | 20 | B2M(1), KLRC1(1), MAP2K1(3), PIK3CA(1), PIK3R1(4), PTK2B(1), SYK(2), VAV1(2) | 1042544 | 15 | 12 | 13 | 1 | 8 | 1 | 1 | 2 | 3 | 0 | 0.014 | 0.0039 | 0.8
4 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | CDKN2A(1), E2F1(2), MDM2(1), PRB1(5), TP53(4) | 471635 | 13 | 9 | 13 | 1 | 7 | 1 | 2 | 1 | 2 | 0 | 0.02 | 0.0058 | 0.89
5 | MITRPATHWAY | The MyoD/MEF2 transcription factors induce muscle cell differentiation and are repressed by the transcriptional repressor MITR. | CAMK1, CAMK1G, HDAC9, MEF2A, MEF2B, MEF2C, MEF2D, MYOD1, YWHAH | 9 | CAMK1(1), CAMK1G(2), HDAC9(6), MEF2B(1), MEF2C(1), MEF2D(1) | 421151 | 12 | 9 | 12 | 1 | 8 | 1 | 0 | 1 | 2 | 0 | 0.024 | 0.014 | 1
6 | GSPATHWAY | Activated G-protein coupled receptors stimulate cAMP production and thus activate protein kinase A, involved in a number of signal transduction pathways. | ADCY1, GNAS, GNB1, GNGT1, PRKACA, PRKAR1A | 6 | ADCY1(3), GNAS(3), PRKACA(1), PRKAR1A(1) | 366518 | 8 | 8 | 7 | 1 | 6 | 0 | 0 | 1 | 1 | 0 | 0.15 | 0.016 | 1
7 | IGF1RPATHWAY | Insulin-like growth factor receptor IGF-1R promotes cell growth and inhibits apoptosis on binding of ligands IGF-1 and 2 via Ras activation and the AKT pathway. | AKT1, BAD, GRB2, HRAS, IGF1R, IRS1, MAP2K1, MAPK1, MAPK3, PIK3CA, PIK3R1, RAF1, SHC1, SOS1, YWHAH | 15 | HRAS(1), IGF1R(1), IRS1(1), MAP2K1(3), PIK3CA(1), PIK3R1(4), SHC1(2), SOS1(1) | 1068570 | 14 | 12 | 12 | 1 | 6 | 0 | 2 | 2 | 4 | 0 | 0.036 | 0.018 | 1
8 | SA_TRKA_RECEPTOR | The TrkA receptor binds nerve growth factor to activate MAP kinase pathways and promote cell growth. | AKT1, AKT2, AKT3, ARHA, CDKN1A, ELK1, GRB2, HRAS, MAP2K1, MAP2K2, NGFB, NGFR, NTRK1, PIK3CA, PIK3CD, SHC1, SOS1 | 15 | HRAS(1), MAP2K1(3), MAP2K2(1), NGFR(1), NTRK1(4), PIK3CA(1), SHC1(2), SOS1(1) | 899557 | 14 | 12 | 12 | 1 | 8 | 2 | 1 | 2 | 1 | 0 | 0.013 | 0.021 | 1
9 | HSA00130_UBIQUINONE_BIOSYNTHESIS | Genes involved in ubiquinone biosynthesis | COQ2, COQ3, COQ5, COQ6, COQ7, ND1, ND2, ND3, ND4, ND4L, ND5, ND6, NDUFA12, NDUFA13, NDUFB11 | 8 | COQ3(2), COQ5(1), COQ6(1), NDUFA13(1) | 224210 | 5 | 5 | 5 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 0.39 | 0.025 | 1
10 | HSA00902_MONOTERPENOID_BIOSYNTHESIS | Genes involved in monoterpenoid biosynthesis | CYP2C19, CYP2C9 | 2 | CYP2C19(7), CYP2C9(3) | 113730 | 10 | 8 | 10 | 4 | 5 | 1 | 0 | 3 | 1 | 0 | 0.45 | 0.033 | 1

Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2013 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle